Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.

Cho BC, Li W, Spira AI, Sauder M, Feldman J, Bozorgmehr F, Mak M, Smith J, Voon PJ, Liu B, Tian P, Tan JL, Yang CT, Shih JY, Karadurmus N, Cundom JE, Bertollo G, Cicin I, Nieva J, Ortega-Granados AL, Tomasini P, Nguyen D, Felip E, Schuchard J, Murphy SP, Anderson BG, Romero T, Xia Y, Sheng S, Bauml JM, Mahadevia PJ, Kam J, Nematian-Samani M, Simoes J, Wildgust M, Girard N

Open source

DOI
10.1016/j.jtho.2025.07.117
Published
2025 Oct
Container
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Publisher
Not recorded
Open access
no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.jtho.2025.07.117,
  title = {Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.},
  author = {Cho BC and Li W and Spira AI and Sauder M and Feldman J and Bozorgmehr F and Mak M and Smith J and Voon PJ and Liu B and Tian P and Tan JL and Yang CT and Shih JY and Karadurmus N and Cundom JE and Bertollo G and Cicin I and Nieva J and Ortega-Granados AL and Tomasini P and Nguyen D and Felip E and Schuchard J and Murphy SP and Anderson BG and Romero T and Xia Y and Sheng S and Bauml JM and Mahadevia PJ and Kam J and Nematian-Samani M and Simoes J and Wildgust M and Girard N},
  year = {2025},
  journal = {Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  doi = {10.1016/j.jtho.2025.07.117},
  url = {https://doi.org/10.1016/j.jtho.2025.07.117}
}

RIS

TY  - JOUR
TI  - Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.
AU  - Cho BC
AU  - Li W
AU  - Spira AI
AU  - Sauder M
AU  - Feldman J
AU  - Bozorgmehr F
AU  - Mak M
AU  - Smith J
AU  - Voon PJ
AU  - Liu B
AU  - Tian P
AU  - Tan JL
AU  - Yang CT
AU  - Shih JY
AU  - Karadurmus N
AU  - Cundom JE
AU  - Bertollo G
AU  - Cicin I
AU  - Nieva J
AU  - Ortega-Granados AL
AU  - Tomasini P
AU  - Nguyen D
AU  - Felip E
AU  - Schuchard J
AU  - Murphy SP
AU  - Anderson BG
AU  - Romero T
AU  - Xia Y
AU  - Sheng S
AU  - Bauml JM
AU  - Mahadevia PJ
AU  - Kam J
AU  - Nematian-Samani M
AU  - Simoes J
AU  - Wildgust M
AU  - Girard N
PY  - 2025
JO  - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
DO  - 10.1016/j.jtho.2025.07.117
UR  - https://doi.org/10.1016/j.jtho.2025.07.117
ER  - 

APA

BC, C., W, L., AI, S., M, S., J, F., F, B., M, M., J, S., PJ, V., B, L., P, T., JL, T., CT, Y., JY, S., N, K., JE, C., G, B., I, C., J, N., AL, O., P, T., D, N., E, F., J, S., SP, M., BG, A., T, R., Y, X., S, S., JM, B., PJ, M., J, K., M, N., J, S., M, W., & N, G. (2025). Enhanced Versus Standard Dermatologic Management With Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC: The COCOON Global Randomized Controlled Trial.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. https://doi.org/10.1016/j.jtho.2025.07.117

Source records